Sarepta pushes off debt payments in bid to regain financial footing
Written by
BioPharma Dive
Published
0
comments
0
min
A refinancing deal will delay the maturity of $700 million in debt until 2030, allowing the company to “fully fund” its pipeline and meet its near-term financial obligations, CEO Doug Ingram said.